Specialties

Poor medication persistence remains one of the hardest barriers to long-term blood pressure control. For people with diabetes, the stakes are especially high because hypertension adds to cardiovascular and kidney risk. Now, research into RNAi for hypertension in people with diabetes is raising an intriguing possibility: could an injection given …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually …

Diabetic foot ulcer offloading is one of the most important parts of treating a neuropathic plantar ulcer, yet the most effective approaches are still not routinely used. Non-removable knee-high devices, including total contact casts and non-removable walkers, can reduce damaging pressure while supporting wound healing. So why does a treatment …

Continuous glucose monitors (CGMs) and insulin pumps can transform diabetes management, but the technology only works when patients can comfortably keep wearing it. CGM skin irritation can turn a valuable device into a daily source of itching, redness, pain, or damaged skin. In some cases, the reaction becomes severe enough …

For people with diabetes, a retinal photograph has traditionally answered one major question: Is diabetic retinopathy developing? However, artificial intelligence is beginning to uncover much more. Emerging retinal AI models for systemic risk assessment can detect patterns associated with cardiovascular disease, kidney disease, blood pressure, and metabolic health. As a …

For many people with diabetes, lowering LDL cholesterol is a major part of preventing heart attack and stroke. Yet an important clinical puzzle remains. Why do some patients experience cardiovascular events even after LDL reaches recommended targets? Growing evidence points toward lipoprotein(a), or Lp(a), as one possible piece of that …

Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …

Artificial intelligence is rapidly changing how healthcare professionals diagnose disease. But can computers identify kidney damage before it becomes obvious under a microscope? Researchers believe the answer may be yes. The combination of digital pathology, artificial intelligence, and diabetic kidney disease research is opening new opportunities to identify microscopic kidney …

Diabetes care has advanced dramatically over the past decade. While therapies such as GLP-1 receptor agonists and SGLT2 inhibitors have transformed glucose management and cardiovascular outcomes, many patients continue to develop long-term complications. Could an older therapeutic target finally provide the missing piece? Interest in aldose reductase inhibitors for diabetes …

For years, lowering LDL cholesterol has been the cornerstone of preventing heart disease in people with diabetes. Statins and other cholesterol-lowering therapies have dramatically reduced cardiovascular events. Yet many patients continue to experience heart attacks, strokes, or other cardiovascular complications despite reaching recommended LDL cholesterol goals. Why does this happen? …